Irene M. Ghobrial, MD, on How COVID-19 is Changing the Conduct of Clinical Trials
COVID-19 and Cancer CareIrene M. Ghobrial, MD, of Dana-Farber Cancer Institute, talks about PROMISE—her screening study for people at high-risk of developing precursor conditions of multiple myeloma—and how this and other trials have been altered in the wake of the pandemic, as well as what might be considered a silver lining to the crisis. Filmed March 30, 2020.
Related Videos
Laura C. Michaelis, MD: In My Experience Question 4
At this time, would you consider pausing therapy—specifically signaling inhibitors and/or monoclonal antibodies—in patients with chronic lymphocytic leukemia?
Recorded April 24...
Rafal Dziadziuszko, MD, PhD, on Using Telemedicine During the Pandemic: Experience in Poland
Rafal Dziadziuszko, MD, PhD, of the Medical University of Gdansk, talks about the adjustments to cancer care that he and his colleagues have made, how and when they employ te...
Mehdi Hamadani, MD: In My Experience Question 2
During the COVID-19 pandemic, when and why would you consider delaying autologous transplant for patients with diffuse large B-cell lymphoma in second complete remission?
Mehdi Hamadani, MD: In My Experience Question 6
Are you proceeding with front-line autologous transplant in patients with mantle cell lymphoma or delaying it during the COVID-19 pandemic?
Recorded April 21, 2020.
Eduardo L. Cazap, MD, PhD, on COVID-19: The View From South America
Eduardo L. Cazap, MD, PhD, of the Sociedad Latinoamericana y del Caribe de Oncología Médica, and an international editor on The ASCO Post Editorial Board, talks about the sit...
